Copper and anti-anhedonic effect of ketamine in treatment-resistant depression

Słupski, Jakub; Cubała, Wiesław Jerzy; Górska, Natalia; Słupska, Anita; Gałuszko-Węgielnik, Maria

doi:10.1016/j.mehy.2020.110268

Cited by 19 publications

(15 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study population includes subjects enrolled in a naturalistic observational registry protocol for intravenous ketamine treatment in TRD: A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders (GDKet) (NCT04226963). Detailed methodology is discussed elsewhere ( 19 ). The present study comprises a population of 41 patients (26 females) with a mean age of 48.5 years (SD 14.3), with depressive episodes without psychotic features in the course of a major depressive disorder or bipolar disorder.…”

Section: Methodsmentioning

confidence: 99%

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

et al. 2021

Self Cite

View full text Add to dashboard Cite

Anhedonia constitutes one of the main symptoms of depressive episode. It correlates with suicidality and significantly effects the quality of patient's lives. Available treatments are not sufficient against this group of symptoms. Ketamine is a novel, rapid acting strategy for treatment resistant depression. Here we report the change in symptoms of anhedonia measured by Snaith-Hamilton Pleasure Scale as an effect of eight ketamine infusions as an add-on treatment in 42 patients with treatment resistant depression. We also determined the effect of this change on the severity of depressive symptoms measured by Inventory for Depression Symptomatology-Self Report 30-Item (IDS-SR 30). We have observed statistically significant decrease in the level of anhedonia during ketamine treatment. After adjusting for potential confounders we have found that significant reduction in Snaith-Hamilton Pleasure Scale (SHAPS) after each infusion and 1 week post treatment was observed only among patients who did not use benzodiazepines. The reduction in symptoms of anhedonia mediates the antidepressive effect of ketamine. The results need replication in a larger randomized placebo controlled trial.

show abstract

Section: Methodsmentioning

confidence: 99%

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The sample selection methods for this study have been described in detail elsewhere. 9 , 10 Briefly, the patient sample comprised subjects enrolled in a naturalistic observational safety and efficacy registry protocol for ketamine infusions in TRD. Inpatients diagnosed with TRD-MDD and TRD-BP were included.…”

Section: Methods and Populationmentioning

confidence: 99%

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Włodarczyk

Cubała

Gałuszko-Węgielnik

et al. 2021

Therapeutic Advances in Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Background: There is evidence supporting the use of ketamine in treatment-resistant depression (TRD). However, there are some safety and tolerability concerns associated with ketamine. This study aimed to investigate ketamine’s safety and tolerability to the central nervous system and to assess the relationship between dissociative symptomology and psychometric outcomes during and after intravenous ketamine treatment concurrent with treatment by varying psychotropic medications in treatment-refractory inpatients with major depressive disorder (MDD) and bipolar disorder (BP). Methods: A total of 49 patients with MDD and BP were included in this study. The subjects were administered ketamine and were assessed for changes using an observational protocol. Results: No antidepressants were associated with psychomimetic symptomatology except for citalopram ( p = 0.019). Patients treated with citalopram showed a higher intensity of psychomimetic symptomatology. The use of classic mood-stabilizers was significantly associated with an increase in psychomimetic symptomatology according to the Brief Psychiatric Rating Scale (BPRS; lamotrigine p = 0.009, valproate p = 0.048, lithium p = 0.012). No sequelae were observed. Conclusions: Despite the limitations that this study may be underpowered due to the small sample size, the sample consisted of a heterogeneous TRD population in a single site, and there no blinding of who underwent only acute ketamine administration, our observations indicate ketamine use requires close safety and tolerability monitoring with regards to psychomimetic and dissociative symptoms in TRD-BP and careful management for MDD patients. ClinicalTrials.gov identifier: NCT04226963

show abstract

“…The methodology is described in detail elsewhere. 21 The present study comprises a population of thirteen patients with depressive episodes without psychotic features in the course of bipolar disorder. Patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).…”

Section: Materials and Methods Patientsmentioning

confidence: 99%

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study

Wilkowska¹,

Włodarczyk²,

Gałuszko-Węgielnik³

et al. 2021

NDT

Self Cite

View full text Add to dashboard Cite

Purpose Bipolar disorder is a chronic and recurrent condition often associated with treatment resistance and suicidality. There is an unmet need for effective treatment in this group of patients. Ketamine has been demonstrated to have antidepressant and antisuicidal properties in unipolar depression. Most of the available studies concern unipolar depression. Here, we present the efficacy and safety of IV ketamine as an add-on treatment in patients with bipolar I and bipolar II depression. Patients and Methods Thirteen patients with treatment-resistant bipolar depression (TRBD) received eight IV infusions of 0.5 mg/kg ketamine twice a week over four weeks. This is an open-label naturalistic observational study. Ketamine is an add-on treatment. Depressive symptoms were measured with the Montgomery–Asberg Depression Rating Scale (MADRS), and manic symptoms were measured with the Young Mania Rating Scale (YMRS). Psychomimetic symptoms were assessed with the Clinician-Administered Dissociative States Scale (CADSS) and the Brief Psychiatric Rating Scale (BPRS). Results The rates of response and remission after the seventh infusion of ketamine were 61.5% and 46.2%, respectively. A significant antisuicidal effect was observed in responders at the 7th infusion. Suicidality was measured with item 10 on the MADRS scale. The average time to respond was between 21.1 and 23.2 days to remission. There was an increase in the CADSS scores during the treatment compared to baseline and follow-up, but no differences between responders and non-responders were observed. No affective switch was observed according to the YMRS scale scores. Ketamine treatment was associated with a transient increase in arterial blood pressure. No serious adverse events, however, were observed. Conclusion This report presents the preliminary results of IV ketamine effectiveness and safety in treatment-resistant bipolar depression. The findings suggest that it is a feasible, safe and well-tolerated treatment option in this group of patients. There is a definite need for more studies in this field.

show abstract

Copper and anti-anhedonic effect of ketamine in treatment-resistant depression

Cited by 19 publications

References 49 publications

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study

Contact Info

Product

Resources

About